These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 21772253)

  • 1. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
    Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
    Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
    J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
    Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
    Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
    Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
    Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
    Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
    Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
    Perna SK; Pagliara D; Mahendravada A; Liu H; Brenner MK; Savoldo B; Dotti G
    Clin Cancer Res; 2014 Jan; 20(1):131-9. PubMed ID: 24097874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
    Rossig C; Bollard CM; Nuchtern JG; Rooney CM; Brenner MK
    Blood; 2002 Mar; 99(6):2009-16. PubMed ID: 11877273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
    Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
    Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.
    Ricciardelli I; Blundell MP; Brewin J; Thrasher A; Pule M; Amrolia PJ
    Blood; 2014 Oct; 124(16):2514-22. PubMed ID: 25185261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 17. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer.
    Clémenceau B; Valsesia-Wittmann S; Jallas AC; Vivien R; Rousseau R; Marabelle A; Caux C; Vié H
    J Immunol Res; 2015; 2015():482089. PubMed ID: 26665156
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
    Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
    J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.